Full Text View
Tabular View
No Study Results Posted
Related Studies
Study of Rifampicin in Multiple System Atrophy (MSA)
This study has been completed.
Study NCT01287221   Information provided by Mayo Clinic

First Received on January 28, 2011.   Last Updated on January 3, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Multiple System Atrophy
Additional conditions recognized in this trial
Atrophy
Shy-Drager Syndrome
More general conditions related to this trial
Autonomic Nervous System Diseases
Basal Ganglia Diseases
Brain Diseases
Cardiovascular Diseases
Central Nervous System Diseases
Hypotension
Movement Disorders
Nervous System Diseases
Neurodegenerative Diseases
Pathological Conditions, Anatomical
Primary Dysautonomias
Vascular Diseases
Interventions listed in this trial
Rifampicin
placebo
Additional drug interventions recognized in this trial
Riboflavin
Rifampin
More general drug interventions related to this trial
Anti-Bacterial Agents
Anti-Infective Agents
Antibiotics, Antitubercular
Antitubercular Agents
Dermatologic Agents
Enzyme Inhibitors
Growth Substances
Leprostatic Agents
Micronutrients
Molecular Mechanisms of Pharmacological Action
Nucleic Acid Synthesis Inhibitors
Pharmacologic Actions
Photosensitizing Agents
Physiological Effects of Drugs
Radiation-Sensitizing Agents
Therapeutic Uses
Vitamin B Complex
Vitamins
Sponsors listed in this trial
Phillip Low
National Institute of Neurological Disorders and Stroke (NINDS)
Vanderbilt University


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services